Dokkyo Medical University · Saitama Medical Center: Department of Diabetes, Endocrinology and Hematology · 糖尿病内分泌・血液内科 病院准教授

Research keywordstype 2 diabetes・oral semaglutide・hemoglobin A1c interference・telemedicine diabetes care・skin autofluorescence・SGLT2 inhibitors・GLP-1 physiology

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Analysis of five cases showing false-high Hemoglobin A1c due to reduced catalase activity., Hara K, Ujiie A, Suzuki S, Okumura T, Kubo M, Shinozaki H, Yamauchi M, Tsuchiya T, Takebayashi K, Shimozawa N, Koga M, Hashimoto K, Endocr J, 71, 39-44, 2024年2024 · 論文
• Effects of telemedicine on the management of diabetes mellitus in the COVID-19 pandemic- A single center study-., Furukawa S, Kawai S, Yamauchi M, Shinozaki H, Ujiie A, Okumura T, Kubo M, Suzuki S, Asai K, Takii H, Hara K, Miyakawa K, Hara K, Tsuchiya T, Takebayashi K, Hashimoto K, Dokkyo Med J, 2023年2023 · 論文
• Changing from a Dipeptidyl Peptidase (DPP)-4 Inhibitor to Oral Semaglutide in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Observational Study., Takebayashi K, Yamauchi M, Hara K, Tsuchiya T, Hashimoto K., Dokkyo Medical J., 2（Jun）, 123-129, 2023年2023 · 論文
• Switching from a dipeptidyl peptidase (DPP)-4 inhibitor to oral semaglutide in patients with poorly controlled type 2 diabetes: an observational study., Takebayashi K, Yamauchi M, Hara K, Tsuchiya T, Hashimoto K., 2022年2022 · 論文

• Official profile